The Food and Drug Administration (FDA) has accepted for Priority Review the New Drug Application (NDA) for troriluzole for the treatment of adults with ...
The annual event, held Dec. 6, 2024, at the JW Marriott Tampa Water Street, raised funds for the Friedreich’s Ataxia Research ...
News Medical on MSN17h
Gene therapy breakthrough offers hope for severe Dravet syndrome casesAAV-Navβ1 gene therapy effectively reduces seizures and prolongs life in a mouse model of SCN1B-linked Dravet syndrome, ...
In exchange for $165 million, Biogen now has access to zorevunersen, a potential first-of-its-kind treatment for Dravet syndrome.
Day 90 biopsy data reported from first 3 participants dosed in Phase 1/2 INSPIRE DUCHENNE trial —— Average microdystrophin expression of 110% ...
Inspira Achieves Positive Results of Above 95% For Preventing Bloodstream Infections Inspira announced its bio-electronic ...
6don MSN
Biogen expects Leqembi and new rare disease and depression treatments to help offset revenue lost from multiple sclerosis ...
Q4 2024 Earnings Call Transcript February 12, 2025 Operator: Good morning. My name is Jennifer and I will be your conference ...
At this time, I'd like to welcome everyone to the Biogen fourth-quarter and full-year 2024 earnings call and business update. (Operator Instructions) Today's conference is being recorded. Thank you. I ...
News Medical on MSN5d
Flu poses higher neurologic risk for children with underlying conditionsMany clinicians do not consider neurologic complications of the flu when discussing vaccination or treatment of influenza ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback